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1. Introduction
   Vaccine safety relates to the adverse event following immunization 
with the vaccine[1], and the most common cause of vaccine-
related adverse events is human error which stems from logistics 
problems. Hence, all attempts should be taken to retain the safety 
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Objective: To check the effects of the vaccines on the hematopoietic system and weight of 
mice after immunization. 
Methods: The study was done with the Expanded Programme on Immunization vaccines 
donated by the Ministries of Health of Abia and Imo States of Nigeria. The vaccines were 
collected from the cold-chain stores and transported in vaccine carriers to the cold-chain 
facility in Nnamdi Azikiwe University Teaching Hospital within 3 hours of collection. They 
were used to immunize a total of 160 mice. The Ethics Committee of Nnamdi Azikiwe 
University Teaching Hospital, Nnewi of Anambra State, Nigeria approved the protocol.
Results: Mice body weight changes test showed that the mice all had increased body weight at 
Days 3 and 7 post-immunization and none died during the 7 d post-immunization observation. 
The percentage weight gains of the mice compared with the control were 69%, 70%, 64%, 
63%, 65% and 68% for oral polio vaccine, diphtheria-pertussis-tetanus, bacillus Calmette–
Guérin, measles, yellow fever and hepatitis B vaccines respectively collected from Imo State. 
The mice immunized with oral polio vaccine, pentavalent, bacillus Calmette–Guérin, measles, 
yellow fever and hepatitis B vaccines collected from Abia State had 123%, 114%, 121%, 
116%, 142% and 119% weight gain respectively compared with the control. Leukocytosis 
promoting toxicity test showed that none of the vaccines was able to induce proliferation 
of leukocytes up to ten folds. Leukopenic toxicity test showed that all the vaccines had an 
leukopenic toxicity test value higher than 80% of the control (physiological saline). 
Conclusions: The vaccine samples tested were safe and did not affect the hematopoietic 
system adversely. The storage conditions of the vaccines in the States’ cold-chain stores had 
not compromised the safety of the vaccines.
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of the vaccine. Allergic reactions to vaccine components, although 
rare, are important issue to consider[2]. Safety is an obligatory 
requirement for a vaccine, be it human or animal. Adverse effects 
can have a strong negative effect on immunization coverage, as 
the benefits of vaccination may not be directly clear for individual 
vaccinees, but adverse effects are immediately apparent. Vaccine 
safety is maintained by developing consistent production processes, 
extensive safety testing and post-marketing surveillance. Safety 
tests are also done to prevent more serious adverse events. Potential 
safety problems of attenuated vaccines are reversion to wild type. 
The potential risk of inactivated vaccines is that they are not killed 
or detoxified completely[3]. Vaccine safety is a prime concern for 
the public, manufacturers, immunization providers and recipients of 
vaccines[4].
   Just like other pharmaceutical products, no vaccine is completely 
safe, which is being prone to adverse effects. This safety question 
is heightened when the vaccines poorly stored. Being biological 
products, they deteriorate faster when are poorly stored and so 
become unsafe for use in immunization programme. While almost 
all known vaccine adverse events are minor and self-limited, some 
vaccines have been associated with very rare but serious health 
effects[5-7].
   The study sets to determine how safe the childhood immunization 
vaccines in use in Abia and Imo States of Nigeria are.
2. Materials and methods
2.1. Animals used and method of identification
   This study used 70 albino mice grouped randomly into 7 with each 
group containing 10 mice. The commonly used methods for labeling 
the animals used in biomedical research are temporary identification 
method and permanent identification method[8,9]. Temporary 
identification methods (employed in this study) involved the use of 
permanent markers to mark the tail, fur or skin of the animals. The 
marks were renewed every 2 days. Permanent identification method 
includes tattooing, use of ear punches, microchip transponders 
and ear tags. The temporary identification method was used in 
this study and the marks were renewed every 2 days. All animals 
[(30±5) days old] were treated in accordance with the guidelines to 
promote the wellbeing of animals used for scientific purposes[10,11]. 
2.2. Determination of the toxicity and safety of the vaccines
   The toxicity and safety of the vaccines were determined using 
modified Haruka et al.[12] method and described under the individual 
tests. Modifications were done by the researchers.
2.2.1. Animal body weight changes test
   This is a general safety test for vaccines. A volume of one human 
dose of test vaccine was injected into the peritoneum [except for 
oral polio vaccine (OPV) which was by oral route] of each of the 10 
mice used in this study and observed daily for 7 d. Vaccines were 
considered non-toxic if they meet the following requirements[13-16]: 
(a) the total weight of the mice 3 d post-vaccination is equal to or 
more than the initial weight, (b) at the end of 7 d post-vaccination, 
the average weight gain per mouse in the vaccine group was not 
less than 60% of the control group, and (c) not more than 5% of the 
animals died during the test period and none should show any sign 
of ill health within the 7 d.
2.2.2. Leukocytosis promoting toxicity test using experimental 
animal
   This tests whether or not the vaccine is toxic to the hematopoietic 
system. A volume of one human dose of test vaccine is injected into 
the peritoneum (except for OPV which was by oral route) of 10 mice. 
Before the immunization and 3 d after, 20 µL blood samples of the 
mice were collected in sterile Eppendoff tube using heparinized 
capillary tube inserted just below the eye ball, diluted with Turk’s 
solution (380 µL) and leukocytes [white blood cells (WBC)] count 
done using hemocytometer. The standard criterion of safety is that 
the mean WBC count in peripheral blood 3 d after injection should 
not be greater than 10 times before injection[12,17].
2.2.3. Leukopenic toxicity test in vaccinated animals
   This also tests the toxicity of the vaccines to the hematopoietic 
system using the general safety test and the leukopenic toxicity 
test (LTT). Eighty mice were selected and grouped into A to H 
with each group containing 10 mice. Groups A to F were given a 
volume of one human dose of bacillus Calmette–Guérin (BCG), 
OPV, hepatitis B vaccine (HBV), measles vaccine (MV), yellow fever 
vaccine (YFV) and diphtheria-pertussis-tetanus (DPT) or pentavalent 
vaccine respectively by intra-peritoneum (except for OPV which 
was by oral route). Group G was given cyclophosphamide (400 
mg/kg)[18] by gavage to serve as positive control while Group H 
was given 500 µL of normal saline to serve as negative control. 
Cyclophosphamide for injection was reconstituted with the 0.9% 
sodium chloride injection to make a stock solution of 20 mg/L 
(Biochem Pharmaceutical Industries, India–Lot #: KB116010). 
After 18 h, 20 µL blood samples of the mice were collected in sterile 
Eppendoff tube using heparinized capillary tube inserted just below 
the eye ball, diluted with Turk’s solution (380 µL) and leukocytes 
count done using hemocytometer. The vaccine is considered safe if it 
shows a leukopenic toxicity value greater than or equal to 80% of the 
leukopenic toxicity of the control[12,14,19]. 
Leukopenic toxicity value (LTvalue)=
WBC count (test or control) 
WBC count (toxic substance)
       
2.3. Ethical issues
   
The work described in this article was approved by the Ethics 
Committee of Nnamdi Azikiwe University Teaching Hospital, Nnewi 
(Approval #: NAUTH/CS/66/Vol.4/220)
2.4. Statistical analysis
   The results were analyzed using GraphPad Prism[20]. The statistical 
tests used were: unpaired student’s t-test, analysis of variance (One-
way and Two-way ANOVA), Dunnett’s test of multiple comparison 
and Bartlett’s test for equal variances. All P values reported are for a 
one-tailed test. P<0.05 was considered significantly different.
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3. Results
   All the mice used (or immunized) were observed for 7 d, but none 
showed any abnormality, signs of ill health or died within the period. 
There was increase in the mean body weight in all the animals as 
seen in Table 1.
Table 1
Animal body weight changes test for vaccines from Imo State.
Vaccines Day after 
vaccination
Mice body weight (g)  Weight gain 
compared to 
control (%)
P value
Total 
weight 
Mean weight 
(n=10)
Mean weight 
gain
OPV 0 146.40 14.64 0.00
3 156.00 15.60 0.96  0.221 2
7 211.60 21.16 6.52 69.35 <0.000 1*
DPT 0 165.30 16.53 0.00
3 177.40 17.74 1.21  0.166 7
7 230.70 23.07 6.54 69.87 <0.000 1*
BCG 0 202.30 20.23 0.00
3 215.00 21.50 1.27 0.214 4
7 265.40 26.54 6.31 63.90  0.001 3*
Measles 0 169.20 16.92 0.00
3 178.90 17.89 0.97  0.186 3
7 231.80 23.18 6.26 62.90 <0.000 1*
YFV 0 177.50 17.75 0.00
3 193.00 19.30 1.55 0.187 0
7 241.00 24.10 6.35 64.94  0.000 7*
HBV 0 168.10 16.81 0.00
3 182.00 18.20 1.39  0.127 0
7 232.80 23.28 6.47 68.05 <0.000 1*
Control 
NS
0 188.00 18.80 0.00
3 198.40 19.84 1.04 0.286 5
7 226.50 22.65 3.85  0.024 4*
Control NS: Control using 0.9% normal saline. Day 0 means before 
vaccination. *P<0.05. P value is for student’s t-test.
   Comparing the mean body weight due to the vaccines with their 
initial weights using the student’s t-test, it showed that at 3 d post-
vaccination, all the mice immunized had non-significant weight gain 
(P>0.05). All the vaccines passed the compendia and World Health 
Organization recommendations for abnormal toxicity test of 3 d 
post-vaccination.
   At 7 d post-vaccination, all the mice had significant weight gain 
(P<0.05) compared with their initial weights, and the % weight gains 
(of the animals immunized with BCG, measles and yellow fever 
vaccines) were barely greater than 60% compared to mean weight 
gain of control. These batches of the vaccines, although passed 
the test, must be consumed soonest so that their safety will not be 
compromised.
   Two-way ANOVA of the results of the animal body weight changes 
test showed that both the vaccine type and post-vaccination day 
significantly affected the weight of the animals by 13.28% and 
36.43% respectively (P<0.000 1). However, the vaccine type did not 
have the significant effect at all values affected by post-vaccination 
day (P=0.988 5) as the interaction of the two treatments only 
accounted for 0.95% of the total variance.
   The leukocytosis promoting toxicity test showed that none of the 
vaccines produced up to 10-fold increase of the WBC in the animals 
(Table 2). This compared well with the control. Most of the vaccine, 
except BCG, produced approximately 3-fold increase in leukocyte 
count 3 d post-vaccination–similar to the physiological saline used 
as control. The BCG vaccines, like the physiological saline used 
as control, produced a 2-fold leukocyte increase. A t-test analysis 
showed that the increase in leukocyte count produced by the test 
vaccines and the control were all significant (P<0.05). The Dunnett’s 
multiple comparison test showed non-significant difference in the 
effects of the vaccines when compared with the control. 
Table 2
Leukocytosis promoting toxicity test for vaccines from Imo State.
Vaccines Day of 
vaccination
Leukocyte count (×109/L) WBC increased 
by X folds
P value
Total WBC Mean WBC (n=10)
OPV 0   49.55   4.955 3.02 <0.000 1*
3 149.55 14.955
DPT 0   35.65   3.565 2.71 <0.000 1*
3   96.90   9.690
BCG 0   65.65   6.565 2.36  0.000 9*
3 155.15 15.515
Measles 0   54.90   5.490 2.68 <0.000 1*
3 147.40 14.740
YFV 0   54.35   5.435 2.75 <0.000 1*
3 149.65 14.965
HBV 0   47.05   4.705 3.13 <0.000 1*
3 147.25 14.725
Control NS 0   61.25   6.125 2.36 <0.000 1*
3 144.55 14.455
Day 0 means before vaccination. Control NS: Control using 0.9% normal saline. 
*P<0.05. P value is for student’s t-test.
   A Two-way ANOVA of the results also showed that both the 
vaccine type and post-vaccination day significantly affected the 
leukocyte count by 5.75% and 65.78% respectively (P=0.000 4, 
P<0.000 1 respectively) (Table 2). The vaccine type did not have the 
significant effect at all values affected by post-vaccination day–the 
interaction accounting for only 1.31% of the total variations. This 
meant that the interactions of the two treatments did not significantly 
affect the leukocyte count (P=0.419 2).
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Figure 1. Leukopenic test for vaccines from Abia (A) and Imo (B) States.
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   The LTT showed that the vaccines and the 0.9% sodium chloride 
had the LTvalues of 2.703, 2.778, 2.707, 2.343, 2.498, 2.578 and 2.832 
respectively in the mice used. The LTvalue of each of the vaccine was 
higher than the 80% LTvalue of 0.9% sodium chloride (Figure 1A). 
One-way ANOVA of the mean leukocyte counts showed significant 
difference (P<0.000 1) between the cyclophosphamide and the 
vaccines. Bartlett’s test for equal variances also showed significant 
difference (P=0.002 5).
   Dunnett’s multiple comparison test showed significant differences 
in the mean leukocyte count due to the cyclophosphamide compared 
with those due to the vaccines and the sodium chloride (P<0.05). 
However, a comparison of the counts due to the sodium chloride 
with those due to the vaccines showed no significant difference for 
the vaccines (P>0.05) and the Bartlett’s test for equal variances 
revealed that the variances were different (P=0.023 6).
   One-way analysis of the results of the LTT showed that 
the leukocyte count was significantly affected by all the 
treatments (P<0.000 1)–the vaccines, the normal saline and the 
cyclophosphamide. The Bartlett’s test for equal variances also 
showed that the variances were significant difference (P=0.003 2). 
Dunnett’s multiple comparison test showed that the effects of the 
vaccine type on the leukocyte count were significantly different 
compared with the effect of the leukopenic agent-cyclophosphamide. 
Nevertheless, the vaccines effects on the leukocyte count did not 
differ significantly, showing that the vaccines were as safe as the 
physiological saline (P=0.080 1).
Table 3 
Animal body weight changes test for vaccines from Abia State.
Vaccines Day after 
Vaccination
Mice body weight (g) Weight gain 
compared to 
control (%)
P value
Total 
weight 
Mean weight 
(n=10)
Mean 
weight gain
OPV 0 195.30 19.53 0.00
3 211.20 21.12 1.59  0.081 4
7 255.10 25.51 5.98 123.13 <0.000 1*
Pentavalent 0 194.50 19.45 0.00
3 195.70 19.57 0.12  0.445 3
7 252.10 25.21 5.76 114.93 <0.000 1*
BCG 0 171.80 17.18 0.00
3 178.80 17.88 0.70  0.230 8
7 231.00 23.10 5.92 120.90 <0.000 1*
Measles 0 173.70 17.37 0.00
3 179.80 17.98 0.61  0.211 5
7 231.70 23.17 5.80 116.42 <0.000 1*
YFV 0 186.10 18.61 0.00
3 188.80 18.88 0.27  0.374 3
7 251.00 25.10 6.49 142.16 <0.000 1*
HBV 0 163.80 16.38 0.00
3 173.20 17.32 0.94 0.050 0
7 222.40 22.24 5.86 118.66  0.000 4*
Control 0 166.40 16.64 0.00
3 174.00 17.40 0.76  0.088 7
7 193.20 19.32 2.68  <0.000 1*
Day 0 means before vaccination. *P<0.05. P value is for student’s t-test.
   None of the animals used in the test died or showed any sign of 
ill health throughout the 7 d post-vaccination observation. None 
showed weight loss. Comparing the mean body weights at pre- 
and post-vaccination days, Table 3 shows that there was generally 
non-significant weight gain in all the animals immunized with 
the vaccines under study on 3 d post-vaccination, but there were 
significant weight gains in all the mice on 7 d post-vaccination 
(P<0.05). A comparison of the variances in the mean body weight 
also at the pre- and post-vaccination days showed no significant 
difference (P>0.05). All the vaccines produced more than 100% 
weight gain on 7 d post-vaccination in the immunized mice 
compared to the control. This was an excellent result compared to 
the vaccines procured from the previous statement.
   The vaccines were all still within the acceptable safety as shown 
by the test. Two-way ANOVA of the result of animal body weight 
changes test showed that the animals’ weight was significantly 
affected by both the vaccine type and the post-vaccination period 
(P<0.000 1) but not the interactions of the two (P<0.093 8). The 
vaccine type affected the weight by 17.18%, the post-vaccination 
period caused 50.2% of the changes while the interactions of the two 
accounted for 3.01% of the total variance.
   The Two-way ANOVA of the result of the leukocytosis promoting 
test showed that the leukocyte count was significantly affected by the 
vaccine type, post-vaccination period and the interactions of the two. 
Vaccine type accounted for 8.94% (P<0.000 1), post-vaccination 
period accounted for 49.19% (P<0.000 1) while the interactions of 
the two accounted for 5.51% (P=0.000 61) of the variations in the 
leukocyte count (Table 4).
   The Table 4 shows the leukocytosis promoting toxicity test for the 
vaccines under study as compared with 0.9% sodium chloride. The 
increase in the leukocyte count produced by the vaccines was very 
high comparable with that of the sodium chloride as none increased 
the count by 10-folds. The highest increase was by 2-folds which 
were produced by the OPV, measles and yellow fever vaccines. A 
t-test analysis to compare the effects produced by the individual 
vaccine with leukocyte counts before the vaccine administration 
showed significant differences at pre- and post-vaccination periods 
(P<0.05). Dunnett’s multiple comparison test to compare the effects 
of the vaccines with the 0.9% sodium chloride showed no significant 
difference (P>0.05). Therefore, the increases in the leukocyte 
produced by the vaccines were comparable to that produced by 0.9% 
sodium chloride.
Table 4
Leukocytosis promoting toxicity test for vaccines from Abia State.
Vaccines Day after 
vaccination
Leukocyte count (×109/L) WBC 
increased by 
X folds
P value
Total WBC
Mean WBC 
(n=10)
OPV 0   55.65   5.565
3 118.15 11.815 2.12 <0.000 1*
Pentavalent 0   74.50   7.450
3 129.50 12.950 1.74 <0.000 1*
BCG 0   75.40   7.540
3 129.35 12.935 1.72   0.000 6*
Measles 0   57.70   5.770
3 115.85 11.585 2.01 <0.000 1*
YFV 0   74.10   7.410
3 160.55 16.055 2.17 <0.000 1*
HBV 0   74.25   7.425
3 140.15 14.015 1.89 <0.000 1*
Control NS 0   72.10   7.210
3   89.60   8.960 1.24 <0.000 1*
Day 0 means before vaccination. Control NS: Control using 0.9 % normal saline. 
*P<0.05. P value is for student’s t-test.
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   The LTT showed that the vaccines and the 0.9% sodium chloride 
had the LTvalues of 3.200, 3.537, 3.0967, 3.030, 3.020, 3.126 and 
3.766 respectively. The LTvalue of the vaccines was higher than the 
80% LTvalue of sodium chloride (Figure 1B). Dunnett’s multiple 
comparison test to compare the leukocyte count due to the vaccines 
and the sodium chloride showed no significant difference at P>0.05. 
Also, a comparison of the leukocyte count due to the vaccines with 
the count due to the cyclophosphamide showed marked significant 
differences (P<0.05).
   One-way analysis of the results of the LTT showed that 
the leukocyte count was significantly affected by all the 
treatments (P<0.000 1)–the vaccines, the normal saline and the 
cyclophosphamide. The Bartlett’s test for equal variances was also in 
concordance with the previous statement (P=0.001 2). The Dunnett’s 
multiple comparison test showed that the effects produced by the 
vaccines did not differ significant from each other and from the 
normal saline. However, the effects differed significantly from that 
produced by the leukopenic agent-cyclophosphamide. The vaccines 
were therefore judged to be safe and non-toxic, at least, to the 
hematopoietic systems.   
4. Discussion
   The results of this study showed that the vaccines were safe 
because each did not cause lower mean mouse weight at 3 d post-
vaccination and at 7 d post-vaccination, the percent (%) weight gain 
compared to mean weight gain of control for each vaccine was above 
60%. However, the samples from Abia State have better values 
for the percent (%) weight gain compared to mean weight gain of 
control. This could mean that the samples from Abia were better 
stored and had complete absence of residual toxin and/or chemicals, 
degradation products in the vaccines which results from poor 
vaccine storage. Perkins et al. showed that the pertussis-containing 
vaccines that lower mice body weight could cause adverse reactions 
if administered to children[21]. The results of abnormal toxicity test 
correlates well with vaccine toxicity[22].
   The leukocytosis promoting toxicity test showed that the vaccines 
produce much less than 10-folds increase of the WBC in the 
vaccinated mice. The increase in the leukocytes due to the vaccines 
compares well with that due to the control 0.9% sodium chloride 
showing that the vaccines did not cause any hematopoietic damage. 
These are contrary to the findings of von Elten et al. when they 
demonstrated that pneumococcal vaccines cause leukocytosis and 
fever in vaccinated individuals[23].
   LTT is a test to investigate whether or not a vaccine is capable 
of decreasing the number of eukocytes in vaccinated individuals 
thereby placing them at the risk of infection. The statistical 
analysis (Dunnett’s multiple comparison test) of this study showed 
that the vaccines were similar to the non-toxic reference (0.9% 
sodium chloride) used and significantly different (P<0.05) from 
the toxic reference (the cyclophosphamide). Therefore, they are 
safe as they are not capable of causing leucopenia in vaccinated 
individuals. However it should be understood that live vaccines are 
contraindicated in immuno-compromised individuals for the risk of 
infections and increases leucopenia[24].
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Comments 
Background
   Vaccines stimulate human immune system by mimicking a 
natural infection. The introduction and widespread use of vaccines 
have resulted in dramatic declines in the morbidity, disability, and 
mortality caused by many infectious diseases in the world. Although 
vaccines are developed in accordance with the highest standards of 
safety, licensed vaccines should be continually monitored for safety 
and efficacy before and after immunization.
  
Research frontiers
   This study aims at checking the effects of the vaccines on the 
hematopoietic system and weight of mice after immunization.
Related reports
   Childhood immunization schedule (covering children from birth 
through age 6 years) immunizes children with vaccines that protect 
young children against over 10 pathogens and strives to protect 
children at the youngest, and the most vulnerable age. The post-
marked surveillance of licensed vaccines are important for the safety 
of vaccines. The mouse is chosen as the test species because of its 
acceptance as a predictor of toxic changes in man. 
Innovations and breakthroughs
   The study evaluated the safety of six vaccine products that are 
currently being used for childhood immunization program in 
two states of Nigeria, tested the vaccine products by simple and 
practicable methods, and provided important information about the 
safety of the vaccines.
  
Applications
   The methods used in the study to evaluate the safety of the licensed 
vaccines are simple and affordable for developing countries.
Peer review
   The study evaluated the vaccines that are utilized in routine 
immunization program in Imo and Abia States, Nigeria. The methods 
employed to test the vaccines in mice are body weight change test, 
leukopenic promoting toxicity test, and leukopenic toxicity tests in 
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mice before and after immunization of the mice.
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